Kyowa acquires Lonza production technology
This article was originally published in Scrip
Executive Summary
Kyowa Hakko and its US antibody technology subsidiary BioWa have licensedLonza's glutamine synthetase (GS) gene expression system for use in the production of antibodies and recombinant proteins under development by the Japanese firm. The worldwide, non-exclusive deal adds to the basic research collaboration signed previously by the two firms to examine combining the GS system with BioWa's Potelligent antibody potency-enhancing technology. Kyowa will merge with Japan's Kirin Pharma in October to form Kyowa Hakko Kirin.